Navigation Links
Center Of Reproductive Medicine Participates In The Thrive-IVF Research Study To Help Improve Pregnancy Success Rates And Outcomes In Women With A History Of Repeated In Vitro Fertilization (IVF) Failures
Date:9/26/2013

WEBSTER, Texas, Sept. 26, 2013 /PRNewswire/ -- The Center of Reproductive Medicine today announced its participation in the Thrive-IVF Research Study, a Phase 2 clinical trial sponsored by Nora Therapeutics, Inc., to evaluate the efficacy, safety and tolerability of NT100 in women who have had repeated in vitro fertilization (IVF) failures despite having good quality embryos. A novel biologic agent similar to a naturally occurring protein in the female reproductive tract, NT100, is being specifically designed and developed for use following in vitro fertilization (IVF) procedures to improve pregnancy success rates and outcomes.

"We are delighted to be part of the Thrive-IVF Research Study to help evaluate a unique treatment option that could help improve pregnancy success rates and outcomes for women who have undergone multiple unsuccessful IVF procedures," said Vicki L. Schnell MD, FACOG, Thrive-IVF study investigator, and founder and medical director, Center of Reproductive Medicine.

More than seven million couples in the U.S. suffer from infertility and 10 percent of women of childbearing age in the developed world experience infertility in any given 12-month period. While significant research efforts in IVF have been focused on the embryo, it is estimated that three-fourths of all embryos that are transferred still fail to implant in the uterus. 

A critical part of the equation for the establishment and maintenance of a successful pregnancy is the presence not only of a good embryo, but also a favorable maternal environment for the embryo to implant and thrive. NT100's novel mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. There are currently no FDA-approved therapies focused on this critical dimension of endometrial receptivity.

"Nora believes that the Center of Reproductive Medicine
'/>"/>

SOURCE Nora Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. U.S. Blood Centers Pursue an Evolving Role in Cell Therapies
2. NASA Scientists and Silicon Valley Space Center Partners Make Home Team Bid for Moffett Federal Airfield Development
3. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
4. Blood Centers of America Experiences Record Growth
5. Elekta Opens Global Education Center for Oncology and Neuroscience Professionals
6. Miami’s Preferred Cord Blood Laboratory, GeneCell International, Partakes in North Shore Medical Center and Hialeah Hospital’s OB/GYN Symposium
7. Avon Foundation for Women, NIH, and the Center for Advancing Innovation Launch Start-Up Challenge to Advance Breast Cancer Biomedical Invention
8. TriCore Reference Laboratories Named First Next-Generation Sequencing Center of Excellence by Life Technologies
9. Animal Rehabilitation and Wellness Center Gives Castle Rock Golden Retriever a Second Chance to Enjoy Life with Stem Cell Therapy
10. West Nile Virus Reported from New York to Long Beach; The Center for the Biology of Chronic Disease (CBCD) Urges the Public to Take Precautions
11. Chinese Leader in Genomics Joins Science Center's Port Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... 31, 2015 , ... Regulatory agencies have acknowledged impurities especially ... process. Thus, innovator companies must understand what will be needed in the drug ... been hosting multiple educational panels and seminars for experts to share advice concerning ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Food ... food and beverage processors, equipment manufacturers and leaders in the field of academia. ... weighing and formulation for manufacturers of bakery and snacks; beverages; dairy; meat, poultry ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for ... first commercially available new FDA approved system in the last 14 years, and the ... high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, ...
(Date:8/31/2015)... ... August 31, 2015 , ... Proove Biosciences, Inc. is a finalist for ... High Tech Awards. , Now in its 22nd year, this premier awards event celebrates ... across the nation and around the world. The OC Tech Alliance will announce all ...
Breaking Biology Technology:Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4
... is Superior to Placebo, Similar Efficacy to ... a Day, and Less Daytime Drowsiness, ... (Nasdaq:,CEPH) announced the pooled analysis of two ... (cyclobenzaprine,hydrochloride extended-release capsules), a new once-daily extended-release,skeletal ...
... Quantitative Research ... Worldwide, NEW YORK, ... of those fielded in the US and abroad -- were,conducted online last ... report, released today, indicates that Internet-based market,research -- once the orphan of ...
... Inc. (Nasdaq: ONXX ) today announced that it ... and full year 2007,financial results and provide a business ... Time (2:00 p.m. Pacific Time). Financial results,for the fourth ... released,earlier that day., Interested parties may access a ...
Cached Biology Technology:Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting 2Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting 3Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting 4Technology Transforms Market Research in Pharmaceutical Industry 2Technology Transforms Market Research in Pharmaceutical Industry 3Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast 2
(Date:8/28/2015)... August 28, 2015 According to ... Market by Assessment Type (Pen & Paper Based, Hosted, ... Corporate Learning, Academic Research), Vertical and Region - Global ... Training Market to grow from USD 2.4 Billion in ... Compound Annual Growth Rate (CAGR) of 25.6% from 2015 ...
(Date:8/26/2015)... , August 26, 2015 ... Four, and Five Factor), Application (Travel & Immigration, Government, ... - Global Forecast to 2020", published by MarketsandMarkets, Multi-Factor ... by 2020, growing at a CAGR of 17.7% between ... and 82 F igures spread through 169 ...
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3
... tempers the killing activity of a specific group of immune ... attack tumor cells and cells infected by viruses. The key ... which has been known for a long time and which ... Dr. Armin Rehm together with immunologist Dr. Uta Hpken of ...
... cause plants to store GM proteins in special ,protein ... increasing the overall protein yield. Researchers writing in the ... the mechanism by which the synthetic biopolymer increases the ... a team of researchers from Agriculture and Agri-Food Canada ...
... Heidelberg, Germany, 6 August 2009 The European ... a new private pension plan for EMBO Fellows. The ... needs of highly mobile scientists. Post-doctoral researchers who ... enrolling in the pension plan from 1 January 2010. ...
Cached Biology News:Estrogen-dependent switch tempers killing activity of immune cells 2EMBO pioneers pension plan for internationally mobile postdoctoral researchers 2EMBO pioneers pension plan for internationally mobile postdoctoral researchers 3